Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports

New Perspectives on the Role of Vitiligo in Immune Responses to Melanoma

(2015) Katelyn T. Byrne et al.   Oncotarget

Cytotoxic T lymphocyte responses against melanocytes and melanoma

(2011) Gwendolen Y Chang et al.   Journal of Translational Medicine

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study

(2010) S. J. O'Day et al.   ANNALS OF ONCOLOGY

Determinants of survival in patients with brain metastases from cutaneous melanoma

(2010) M Staudt et al.   BRITISH JOURNAL OF CANCER

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

(2010) Geoffrey Y. Ku et al.   CANCER

Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)

(2010) Anna Maria Di Giacomo et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

(2010) Evan M. Hersh et al.   INVESTIGATIONAL NEW DRUGS

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Brain Metastasis in Melanoma: Clinical Activity of CTLA-4 Antibody Therapy

(2010) Kim A. Margolin et al.   SEMINARS IN ONCOLOGY

Ipilimumab: controversies in its development, utility and autoimmune adverse events

(2009) Jeffrey Weber   CANCER IMMUNOLOGY IMMUNOTHERAPY

Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

(2009) Isabelle Ray-Coquard et al.   CANCER RESEARCH

Do We Need a Different Set of Response Assessment Criteria for Tumor Immunotherapy?

(2009) A. Ribas et al.   CLINICAL CANCER RESEARCH

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

(2009) J. Weber et al.   CLINICAL CANCER RESEARCH

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Final Version of 2009 AJCC Melanoma Staging and Classification

(2009) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

(2009) Jedd D Wolchok et al.   LANCET ONCOLOGY

Prognostic Factors in Metastatic Melanoma Patients Treated with Biochemotherapy and Maintenance Immunotherapy

(2009) D. R. Minor et al.   ONCOLOGIST

Age and gender are significant independent predictors of survival in primary cutaneous melanoma

(2008) Konstantinos Lasithiotakis et al.   CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

(2008) F. S. Hodi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA